Kazuhiko Hayashi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6185360/publications.pdf

Version: 2024-02-01

236612 344852 1,940 129 25 36 citations g-index h-index papers 130 130 130 2937 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 1929-1935.	1.4	112
2	Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice. Metabolism: Clinical and Experimental, 2017, 69, 177-187.	1.5	80
3	Ursodeoxycholic acid induces glutathione synthesis through activation of PI3K/Akt pathway in HepG2 cells. Biochemical Pharmacology, 2009, 77, 858-866.	2.0	58
4	Efficacy of peginterferon- \hat{l} ±-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C. Liver International, 2010, 30, 527-537.	1.9	58
5	Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response. Hepatology Research, 2015, 45, 238-246.	1.8	58
6	A Novel Immunocompetent Rat Model of HCV Infection and Hepatitis. Gastroenterology, 2005, 128, 1416-1423.	0.6	47
7	Changes in Hepatitis C Virus (HCV) Antibody Status in Patients with Chronic Hepatitis C after Eradication of HCV Infection by Interferon Therapy. Clinical Infectious Diseases, 2005, 40, e49-e54.	2.9	46
8	Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000. Cancer, 2004, 100, 2415-2421.	2.0	42
9	A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis?. Clinical Journal of Gastroenterology, 2016, 9, 252-256.	0.4	41
10	Prevalence and clinical implications of occult hepatitis B viral infection in hemophilia patients in Japan. Journal of Medical Virology, 2004, 73, 195-199.	2.5	38
11	siRNA-resistance in treated HCV replicon cells is correlated with the development of specific HCV mutations. Journal of Viral Hepatitis, 2006, 13, 756-761.	1.0	38
12	Ligation of HLA class II molecules promotes sensitivity to CD95 (Fas antigen, APO-1)-mediated apoptosis. European Journal of Immunology, 1995, 25, 2190-2194.	1.6	37
13	DSS colitis promotes tumorigenesis and fibrogenesis in a choline-deficient high-fat diet-induced NASH mouse model. Biochemical and Biophysical Research Communications, 2016, 470, 15-21.	1.0	36
14	Impact of myosteatosis on skeletal muscle volume loss in patients with chronic liver disease. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1659-1666.	1.4	34
15	Epstein–Barr Virus Lytic Reactivation Activates B Cells Polyclonally and Induces Activation-Induced Cytidine Deaminase Expression: A Mechanism Underlying Autoimmunity and Its Contribution to Graves' Disease. Viral Immunology, 2017, 30, 240-249.	0.6	32
16	Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma. PLoS ONE, 2015, 10, e0138776.	1.1	31
17	Efficacy of ribavirin plus interferon-? in patients aged ?60°;½½years with chronic hepatitis C. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 989-995.	1.4	30
18	Association of hepatitis B virus subgenotypes and basal core promoter/precore region variants with the clinical features of patients with acute hepatitis. Journal of Gastroenterology, 2008, 43, 558-564.	2.3	30

#	Article	IF	CITATIONS
19	Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C. Liver International, 2010, 30, 554-559.	1.9	30
20	Interleukin-1 loop model for pathogenesis of Langerhans cell histiocytosis. Cell Communication and Signaling, 2015, 13, 13.	2.7	30
21	Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsyâ€proven Japanese nonâ€alcoholic fatty liver disease patients. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 207-214.	1.4	30
22	Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to pegâ€interferon and ribavirin therapy. Liver International, 2011, 31, 1359-1365.	1.9	29
23	Comparison of Akt/mTOR/4E-BP1 pathway signal activation and mutations of PIK3CA in Merkel cell polyomavirus–positive and Merkel cell polyomavirus–negative carcinomas. Human Pathology, 2015, 46, 210-216.	1.1	28
24	Various copper and iron overload patterns in the livers of patients with Wilson disease and idiopathic copper toxicosis. Medical Molecular Morphology, 2013, 46, 133-140.	0.4	26
25	Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy. Journal of Gastroenterology, 2016, 51, 1081-1089.	2.3	26
26	Liver stiffness reduction correlates with histological characteristics of hepatitis C patients with sustained virological response. Liver International, 2018, 38, 59-67.	1.9	25
27	αâ€fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1001-1008.	1.4	24
28	Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus. PLoS ONE, 2015, 10, e0133515.	1.1	24
29	Prevalence of Hepatitis E Virus IgG Antibody in Japanese Patients with Hemophilia. Intervirology, 2008, 51, 21-25.	1.2	23
30	Raloxifene Ameliorates Liver Fibrosis of Nonalcoholic Steatohepatitis Induced by Choline-Deficient High-Fat Diet in Ovariectomized Mice. Digestive Diseases and Sciences, 2015, 60, 2730-2739.	1.1	23
31	Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos(t)ide analog treatment. Hepatology Research, 2018, 48, E240-E251.	1.8	23
32	A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1b. Journal of Medical Virology, 2007, 79, 35-40.	2.5	22
33	Prevalence and characterization of hepatitis C virus genotype 4 in Japanese hepatitis C carriers. Hepatology Research, 2003, 25, 409-414.	1.8	21
34	Comparison of hepatitis B virus subgenotypes in patients with acute and chronic hepatitis B and absence of lamivudine-resistant strains in acute hepatitis B in Japan. Journal of Medical Virology, 2007, 79, 366-373.	2.5	21
35	Frequent incidence of escape mutants after successful hepatitis B vaccine response and stopping of nucleos(t)ide analogues in liver transplant recipients. Liver Transplantation, 2014, 20, 1211-1220.	1.3	21
36	Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and singleâ€nucleotide polymorphism of interleukinâ€28B with the response to combination therapy with pegylatedâ€interferonâ€alpha 2b and ribavirin. Journal of Medical Virology, 2012, 84, 438-444.	2.5	20

#	Article	lF	CITATIONS
37	Effect of the Dose and Duration of Interferon-Alpha Therapy on the Incidence of Hepatocellular Carcinoma in Noncirrhotic Patients with a Nonsustained Response to Interferon for Chronic Hepatitis C. Oncology, 2001, 61, 134-142.	0.9	19
38	Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C1. Journal of Gastroenterology and Hepatology (Australia), 2001, 16, 1131-1137.	1.4	19
39	Evaluation of a new assay for hepatitis C virus genotyping and viral load determination in patients with chronic hepatitis C. Journal of Virological Methods, 2002, 103, 137-143.	1.0	19
40	Prevalence and clinical characterization of patients with acute hepatitis B induced by lamivudineâ€resistant strains. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 745-749.	1.4	19
41	A functional polymorphism in the epidermal growth factor gene predicts hepatocellular carcinoma risk in Japanese hepatitis C patients. OncoTargets and Therapy, 2013, 6, 1805.	1.0	18
42	Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment. Oncology, 2018, 95, 91-99.	0.9	17
43	Mutations in carboxy-terminal part of E2 including PKR/eIF2α phosphorylation homology domain and interferon sensitivity determining region of nonstructural 5A of hepatitis C virus 1b: Their correlation with response to interferon monotherapy and viral load. World Journal of Gastroenterology, 2006, 12, 3722.	1.4	17
44	Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy. Journal of Viral Hepatitis, 2018, 25, 1446-1451.	1.0	16
45	Epstein–Barr Virus Reactivation-Induced Immunoglobulin Production: Significance on Autoimmunity. Microorganisms, 2020, 8, 1875.	1.6	16
46	Skeletal muscle fat deposition is associated with hepatocellular carcinoma development in patients with chronic liver disease. Nutrition, 2018, 54, 83-88.	1.1	15
47	Epstein–Barr Virus Lytic Reactivation Induces IgG4 Production by Host B Lymphocytes in Graves' Disease Patients and Controls: A Subset of Graves' Disease Is an IgG4-Related Disease-Like Condition. Viral Immunology, 2018, 31, 540-547.	0.6	15
48	Deficiency of sphingomyelin synthase 2 prolongs survival by the inhibition of lymphoma infiltration through ICAMâ€1 reduction. FASEB Journal, 2020, 34, 3838-3854.	0.2	15
49	Mutations in the interferon sensitivityâ€determining region of hepatitis C virus genotype 2a correlate with response to pegylatedâ€interferonâ€alpha 2a monotherapy. Journal of Medical Virology, 2009, 81, 459-466.	2.5	14
50	Patients with Chronic Hepatitis C May be More Sensitive to Iron Hepatotoxicity than Patients with HFE-Hemochromatosis. Internal Medicine, 2010, 49, 2371-2377.	0.3	14
51	Ursodeoxycholic acid inhibits overexpression of P-glycoprotein induced by doxorubicin in HepG2 cells. European Journal of Pharmacology, 2014, 724, 161-167.	1.7	13
52	Safety and complications of interventional radiology for hepatocellular carcinoma in patients with haemophilia and cirrhosis. British Journal of Haematology, 2001, 112, 1071-1073.	1.2	12
53	Prevalence of Hepatitis B Virus Subgenotypes and Basal Core Promoter, Precore Variants in Patients with Acute Hepatitis B in Central Vietnam. Intervirology, 2009, 52, 22-28.	1.2	12
54	High viral load of Merkel cell polyomavirus DNA sequences in Langerhans cell sarcoma tissues. Infectious Agents and Cancer, 2014, 9, 15.	1.2	12

#	Article	IF	CITATIONS
55	Hepatocyte-Specific Depletion of UBXD8 Induces Periportal Steatosis in Mice Fed a High-Fat Diet. PLoS ONE, 2015, 10, e0127114.	1.1	12
56	Liver Fibrosis Indices for Identifying Patients at Low Risk of Developing Hepatocellular Carcinoma after Eradication of HCV. Antiviral Therapy, 2017, 22, 185-193.	0.6	12
57	A novel subtype of GB virus C/hepatitis G virus genotype 1 detected uniquely in patients with hemophilia in Japan. Journal of Medical Virology, 2003, 71 , $385-390$.	2.5	11
58	Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma. Oncology, 2016, 91, 261-266.	0.9	11
59	Low skeletal muscle mass predicts early mortality in cirrhotic patients with acute variceal bleeding. Nutrition, 2017, 42, 87-91.	1.1	11
60	Characteristics and prognosis of hepatocellular carcinoma detected in sustained responders to interferon therapy for chronic hepatitis C. Cancer Detection and Prevention, 2003, 27, 498-502.	2.1	10
61	Thyrotropin Receptor Antibody (TRAb)-IgM Levels Are Markedly Higher Than TRAb-IgG Levels in Graves' Disease Patients and Controls, and TRAb-IgM Production Is Related to Epstein–Barr Virus Reactivation. Viral Immunology, 2016, 29, 459-463.	0.6	10
62	Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis <scp>C</scp> virus genotype 1b infection: Realâ€world data. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1879-1886.	1.4	10
63	Liver stiffness measurement predicts hepatocellular carcinoma development in patients treated with directâ€acting antivirals. JGH Open, 2017, 1, 44-49.	0.7	10
64	Merkel cell polyomavirus and Langerhans cell neoplasm. Cell Communication and Signaling, 2018, 16, 49.	2.7	10
65	TT virus genotype changes frequently in multiply transfused patients with hemophilia but rarely in patients with chronic hepatitis C and in healthy subjects. Transfusion, 2001, 41, 1130-1135.	0.8	9
66	Influence of Age, Sex, and Degree of Liver Fibrosis on the Association Between Serum Alanine Aminotransferase Levels and Liver Inflammation in Patients with Chronic Hepatitis C. Digestive Diseases and Sciences, 2004, 49, 295-299.	1.1	9
67	Mutations in two PKRâ€binding domains in chronic hepatitis C of genotype 3a and correlation with viral loads and interferon responsiveness. Journal of Medical Virology, 2011, 83, 1727-1732.	2.5	9
68	Effect of peginterferon alfaâ€⊋b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis <scp>C</scp> . Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 321-328.	1.4	9
69	Effects of Ursodeoxycholic Acid and Insulin on Palmitate-Induced ROS Production and Down-Regulation of PI3K/Akt Signaling Activity. Biological and Pharmaceutical Bulletin, 2017, 40, 2001-2004.	0.6	9
70	Predictive ability of shear wave elastography for pruritus in chronic hepatitis C patients with sustained virological response. European Journal of Gastroenterology and Hepatology, 2018, 30, 1066-1072.	0.8	9
71	Merkel cell polyomavirus–negative Merkel cell carcinoma is associated with JAKâ€STAT and MEKâ€ERK pathway activation. Cancer Science, 2022, 113, 251-260.	1.7	9
72	Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 1072-1078.	1.4	8

#	Article	IF	CITATIONS
73	Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the <i>IL28B</i> gene in patients infected with HCV genotype 1b. Journal of Medical Virology, 2012, 84, 61-70.	2.5	8
74	Acute-phase ITIH4 levels distinguish multi-system from single-system Langerhans cell histiocytosis via plasma peptidomics. Clinical Proteomics, 2015, 12, 16.	1.1	8
75	Aberrant expression of AID and AID activators of NF-l ^o B and PAX5 is irrelevant to EBV-associated gastric cancers, but is associated with carcinogenesis in certain EBV-non-associated gastric cancers. Oncology Letters, 2017, 13, 4133-4140.	0.8	8
76	Estradiol Affects Epstein–Barr Virus Reactivation-Induced Thyrotropin Receptor Antibody and Immunoglobulin Production in Graves' Disease Patients and Healthy Controls. Viral Immunology, 2018, 31, 486-491.	0.6	8
77	Subclinical Epstein-Barr Virus Primary Infection and Lytic Reactivation Induce Thyrotropin Receptor Autoantibodies. Viral Immunology, 2019, 32, 362-369.	0.6	8
78	HepatitisÂB virusâ€related hepatocellular carcinoma in young adults: Efficacy of nationwide selective vaccination. Hepatology Research, 2020, 50, 182-189.	1.8	8
79	Copper Accumulates in Hemosiderins in Livers of Patients with Iron Overload Syndromes. Journal of Clinical and Translational Hepatology, 2015, 3, 85-92.	0.7	8
80	Epsteinâ€"Barr virus-associated posttransplant lymphoproliferative disorder involving the central nervous system following autologous hematopoietic stem cell transplantation for neuroblastoma. SpringerPlus, 2014, 3, 582.	1.2	7
81	Production of thyrotropin receptor antibodies in acute phase of infectious mononucleosis due to Epstein–Barr virus primary infection: a case report of a child. SpringerPlus, 2015, 4, 456.	1.2	7
82	Cerebellar expression of copper chaperone for superoxide, cytosolic cu/zn-superoxide dismutase, 4-hydroxy-2-nonenal, acrolein and heat shock protein 32 in patients with menkes kinky hair disease: immunohistochemical study. Yonago Acta Medica, 2014, 57, 23-35.	0.3	7
83	Japan-specific subtype of hepatitis C virus genotype 1b, J subtype, has relatively low pathogenicity. Journal of Medical Virology, 2001, 65, 45-51.	2.5	6
84	Ribavirin and Use of Clotting Factors in Patients With Hemophilia and Chronic Hepatitis C. JAMA - Journal of the American Medical Association, 2005, 293, 1187.	3.8	6
85	Comparison of the efficacy of ribavirin plus peginterferon alfaâ€2b for chronic hepatitis C infection in patients with and without coagulation disorders. Journal of Medical Virology, 2013, 85, 228-234.	2.5	6
86	Establishment of a Langerhans cell histiocytosis lesion cell line with dermal dendritic cell characteristics. Oncology Reports, 2015, 33, 171-178.	1.2	6
87	Association of interleukin 28 <scp>B</scp> polymorphism and mutations in the <scp>NS5A</scp> region of hepatitis <scp>C</scp> virus genotype 2 with interferon responsiveness. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 178-183.	1.4	6
88	Comparison of direct sequencing and Invader assay for Y93H mutation and response to interferonâ€free therapy in hepatitis C virus genotype 1b. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 249-255.	1.4	6
89	Rapid increase of platelet counts during antiviral therapy in patients with hepatitisÂC virus infection. Hepatology Research, 2020, 50, 47-56.	1.8	6
90	Impact of early elevation of serum bilirubin during treatment with pegylated interferon and ribavirin in patients with chronic hepatitis C. Hepatology Research, 2010, 40, 963-970.	1.8	5

#	Article	IF	CITATIONS
91	Causes of vertical transmission of hepatitis B virus under the atâ€risk prevention strategy in Japan. Microbiology and Immunology, 2013, 57, 118-121.	0.7	5
92	Occurrence of late relapse of hepatitis C virus confirmed by molecular analysis after sustained virologic response to interferon–ribavirinâ€based therapy. Hepatology Research, 2018, 48, E78-E86.	1.8	5
93	Antifibrotic Effects of 1,25(OH)2D3 on Nonalcoholic Steatohepatitis in Female Mice. Digestive Diseases and Sciences, 2019, 64, 2581-2590.	1.1	5
94	Clinical impact of HFE mutations in Japanese patients with chronic hepatitis C. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1112-1116.	1.4	4
95	Mutations of the interferon sensitivity-determining region (ISDR) correlate with the complexity of hypervariable region (HVR)-1 in the Japanese variant of hepatitis C virus (HCV) type 1b. Journal of Medical Virology, 2004, 74, 54-61.	2.5	3
96	Inclusion bodies of aggregated hemosiderins in liver macrophages. Medical Molecular Morphology, 2017, 50, 205-210.	0.4	3
97	Real World Data of Daclatasvir and Asunaprevir Combination Therapy for HCV Genotype 1b Infection in Patients With RenalÂDysfunction. Clinical Gastroenterology and Hepatology, 2017, 15, 787-788.	2.4	3
98	Utility of Doppler ultrasonography for diagnosing and assessing treatment effects in liver compartment syndrome. Clinical Journal of Gastroenterology, 2017, 10, 265-269.	0.4	3
99	Substitutions in interferon sensitivityâ€determining region and hepatocarcinogenesis after hepatitis C virus eradication. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1904-1911.	1.4	3
100	The case of a liver-transplant recipient with severe acute respiratory syndrome coronavirus 2 infection who had a favorable outcome. Clinical Journal of Gastroenterology, 2021, 14, 842-845.	0.4	3
101	Effect of Ribavirin, in Combination With Interferon in Patients With Hepatitis C, on the Bleeding Risk Associated With Selective Serotonin Reuptake Inhibitors. Journal of Clinical Psychiatry, 2008, 69, 679-680.	1.1	3
102	Pegylated interferon monotherapy in patients with chronic hepatitis <scp>C</scp> with low viremia and its relationship to mutations in the <scp>NS5A</scp> region and the single nucleotide polymorphism of interleukinâ€28 <scp>B</scp> . Hepatology Research, 2013, 43, 580-588.	1.8	2
103	Hepatitis B e Antigen and Hepatitis B Surface Antigen Seroclearance with the Emergence of Lamivudine-associated and Core Mutations Following CD4 Elevation in a Patient with Hepatitis B and HIV. Internal Medicine, 2015, 54, 585-590.	0.3	2
104	Hepatocyte-specific depletion of ubiquitin regulatory X domain containing protein 8 accelerates fibrosis in a mouse non-alcoholic steatohepatitis model. Histochemistry and Cell Biology, 2017, 148, 219-227.	0.8	2
105	The Impact of Hepatitis B Virus Infection on Sustained Virologic Response and HBV Reactivation in Patients with Chronic Hepatitis C who Treated by all-Oral Direct-Acting Antivirals Regimens. Gastroenterology, 2017, 152, S1092-S1093.	0.6	2
106	The Prevalence of Mixed Hepatitis C Virus Genotype Infection and Its Effect on the Response to Direct-Acting Antivirals Therapy. Intervirology, 2019, 62, 23-29.	1.2	2
107	High Level Estradiol Induces EBV Reactivation and EBV gp350/220(+)CD138(+) Double-positive B Cell Population in Graves' Disease Patients and Healthy Controls. Yonago Acta Medica, 2019, 62, 240-243.	0.3	2
108	Possible Relationship Between <i>MYBL1</i> Alterations and Specific Primary Sites in Adenoid Cystic Carcinoma: A Clinicopathological and Molecular Study of 36 Cases. Yonago Acta Medica, 2019, 62, 067-076.	0.3	2

7

#	Article	IF	Citations
109	Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the <i>IL28B</i> gene. Journal of Medical Virology, 2011, 83, 1559-1564.	2.5	1
110	A pediatric case of hepatitis B virus subgenotype A2 in Japan. Clinical Journal of Gastroenterology, 2013, 6, 383-385.	0.4	1
111	Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A‥93. Journal of Medical Virology, 2018, 90, 736-744.	2.5	1
112	Complete response by vitamin K2 analog monotherapy in sorafenibâ€failure advanced hepatocellular carcinoma: A case report. Hepatology Research, 2019, 49, 360-364.	1.8	1
113	Detection of Disease-specific Fusion Genes of Soft Tissue Tumors Using Formalin-fixed Paraffin-embedded Tissues; Its Diagnostic Usefulness and Factors Affecting the Detection Rates. Yonago Acta Medica, 2019, 62, 115-123.	0.3	1
114	A case of eosinophilic esophagitis with GERD-like symptoms. Progress of Digestive Endoscopy, 2013, 83, 90-91.	0.0	1
115	The relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma. Acta Hepatologica Japonica, 2013, 54, 505-506.	0.0	1
116	Multiple Skin Cancers in a Renal Transplant Recipient: A Patient Report with Analyses of Human Papillomavirus and Human Polyomavirus Infection. Yonago Acta Medica, 2015, 58, 145-50.	0.3	1
117	The Use of Flexible Hysterofiberscope (FUJINON) in Transcervical Chorionic Villi Sampling, and Its Evaluation. Congenital Anomalies (discontinued), 1989, 29, 91-101.	0.3	0
118	Methods and conclusions in the clinical study of TT virus. Hepatology, 1999, 30, 1335-1335.	3.6	0
119	Re: transient marked decrease in serum transaminases in chronic hepatitis C after surgery. American Journal of Gastroenterology, 2000, 95, 1090-1091.	0.2	0
120	Successful cessation of lamivudine using interferon in a patient with chronic hepatitisÂB who received prophylactic lamivudine treatment during chemotherapy. Clinical Journal of Gastroenterology, 2009, 2, 210-213.	0.4	0
121	Additional Effect of Ribavirin During Peginterferon and Ribavirin Combination Therapy in Coagulation Factor. Gastroenterology, 2011, 140, S-950.	0.6	0
122	Associations between responses to interferon therapy and genetic variation in interleukinâ€28B and the core region of hepatitis C virus genotype 3a. Journal of Medical Virology, 2015, 87, 1361-1367.	2.5	0
123	Tu1670 Core 1971 Mutation Is Associated With Persistent Low HBVDNA and HBsAg Clearance in Patients With Chronic Hepatitis B. Gastroenterology, 2016, 150, S1163.	0.6	0
124	The Association Between Amino Acid Substitutions in the NS5A Region of Hepatitis C Virus and Development of Hepatocellular Carcinoma After Sustained Virological Response. Gastroenterology, 2017, 152, S1162.	0.6	0
125	Impact of HBV Infection on Outcomes of Direct-Acting Antiviral Therapy of Chronic Hepatitis C., 0,,.		0
126	A case of type A gastritis accompanied by eosinophil infiltration in the gastric and duodenal mucosa. Progress of Digestive Endoscopy, 2017, 91, 152-153.	0.0	0

#	Article	IF	CITATIONS
127	Study on re-establishment of ovulation after termination of sex-steroidal treatment. Compared with re-appearance of ovulation after abortion and premature delivery Keio Journal of Medicine, 1979, 28, 173-193.	0.5	0
128	Hepatitis C Treatment in Elderly Patients., 0,,.		0
129	TRAb-IgM induced by Epstein-Barr virus reactivation does not have thyroid stimulating effect, but injures the thyroid follicular epithelial cells and releases thyroid antigens. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2022, 95, 1-O-016.	0.0	0